Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
Patient was delayed receiving their second dose of Rabavert, received the second dose six days after fist dose; Case reference number US-BN-2025-001756 is a spontaneous case initially received from a pharmacist via Bavarian Nordic (reference number: CASE-000567) on 03-Nov-2025 and concerns a patient of an unknown age and gender. The patient's medical history and concomitant medications details were provided. On an unspecified date, the patient had exposure to the animal. On 24-Oct-2025, unknown of time after exposure to animal, the patient received the first dose of RabAvert along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, site, or route of administration for the indication post-exposure prophylaxis and HRIG (batch number: unknown), the dose, route or site of administration were unknown, for indication post-exposure prophylaxis. On 30-Oct-2025, unknown of time after exposure to animal, and six days after the first dose, the patient received the second dose of RabAvert along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose and route of administration, or route of administration (explicitly coded as 'inappropriate schedule of product administration'). At the time of the initial report, it was unknown whether the patient experienced any adverse events due to RabAvert. No further information was provided.; Reporter's Comments: This case concerns a patient of an unknown age and gender, who received first dose of RabAvert vaccine for an indication of post-exposure prophylaxis. As reported patient received the second dose, 6 days after the first dose, which is considered as inappropriate schedule of product administration. Inappropriate schedule of product administration is considered listed per company convention. Patient's medical history and concomitant medication details were not provided. At the time of the initial report, it was unknown whether the patient experienced any adverse events due to RabAvert. Inappropriate schedule of product administration is assessed as not related to suspect vaccine, but to human factor. The case is non-serious.; Sender's Comments: This case concerns a patient of an unknown age and gender, who received first dose of RabAvert vaccine for an indication of post-exposure prophylaxis. As reported patient received the second dose, 6 days after the first dose, which is considered as inappropriate schedule of product administration. Inappropriate schedule of product administration is considered listed per company convention. Patient's medical history and concomitant medication details were not provided. At the time of the initial report, it was unknown whether the patient experienced any adverse events due to RabAvert. Inappropriate schedule of product administration is assessed as not related to suspect vaccine, but to human factor. The case is non-serious.
Comments: None
HRIG